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Abstract
Newer technologies to treat many mental illnesses have shown substantial heterogeneity in
diffusion rates across states. In this paper, I investigate whether variation in the level of managed
care penetration is associated with changes in state-level diffusion of three newer classes of
psychotropic medications in fee-for-service Medicaid programs from 1991-2005. Three different
types of managed care programs are examined: capitated managed care, any type of managed care
and behavioral health carve-outs. A fourth order polynomial fixed effect regression model is used
to model the diffusion path of newer antidepressant and antipsychotic medications controlling for
time-varying state characteristics. Substantial differences are found in the diffusion paths by the
degree of managed care use in each state Medicaid program. The largest effect is seen through
spillover effects of capitated managed care programs; states with greater capitated managed care
have greater initial shares of newer psychotropic medications. The influence of carve-outs and of
all types of managed care combined on the diffusion path was modest.
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1. Introduction
Drug diffusion is an important marker of medical innovation and dissemination, describing
the rate at which drugs are used in a defined population. In markets where under-use is
thought to be an inefficient solution, such as most psychotropic drug markets, greater use of
drug products may indicate gains at the external margin and thus a higher treated prevalence
(Frank and Glied 2006) and more time under clinically improved conditions (Wells 1991;
Kessler, Merikangas et al. 2007). Knowledge concerning the diffusion process would be of
particular help to state Medicaid programs, for many are experimenting with components of
behavioral health insurance without fully understanding consequences for spending and
outcomes.
Psychotropic medications are a particularly interesting class of drugs to examine. Spending
on psychotropic medications is growing rapidly and comprises a substantial portion of total
behavioral health dollars. In 2003, psychotropic medications comprised an estimated 23
percent of total mental health care treatment expenditures (Mark, Levit et al. 2007).
Psychotropic medications were the 4th largest class of outpatient medications sold in the
U.S. in 2006 ranked by expenditure (Soni 2009).
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Psychotropic medication diffusion has been inconsistent across patient populations and
across regions. The reasons for differences in diffusion rates are complex (Drake, Skinner et
al. 2008). State-level differences in diffusion may be motivated by a myriad of factors,
including social capital, or state investments in its population, as well as relative wealth and
degree of interaction among prescribers (Domino, Frank et al. 2009). State-level differences
have been found to affect the diffusion of a wide array of technologies. Skinner and Staiger
(2007) found that the same states that were early adopters of hybrid corn in Griliches' classic
study (1957) were also likely to be early adopters of a diverse array of products including
home computers and beta-blockers after hospitalizations for myocardial infarction.
Differences in social capital measures and state educational investment measures such as
1928 graduation rates from high school among states were strongly predictive of these
differences, but other state factors such as population density or per capita income were not.
Managed care and other health care investments were not among the factors examined, but
are potentially correlated with other investments made by states.
The goal of this manuscript is to contribute to a better understanding of the promoters and
inhibitors of psychotropic drug diffusion in the Medicaid population by examining the
association between managed care penetration and psychotropic drug use. Diffusion of
psychotropic medications in a Medicaid population may in fact mirror diffusion in other
populations; Goldman and Smith (2005), for example, found no difference in the diffusion
of new pharmaceutical technologies for hypertension by socioeconomic status. I employ a
novel econometric method for the estimation of diffusion curves that is in many ways
superior to the widely-used logistic models. I use nationwide information on medication use
in state Medicaid programs from 1991-2005 to characterize the diffusion of three new
classes of psychotropic medications: selective serotonin reuptake inhibitors (SSRI) and
selective serotonin-norepinephrine reuptake inhibitors (SNRI) antidepressants and atypical
antipsychotic (also called second generation antipsychotics, or SGA) medications. Both
SSRIs and SGAs were introduced in the late 1980s and have diffused quite rapidly. SNRIs
were introduced in 1994 and have not diffused as quickly. The diffusion of all three product
areas has been very uneven across different states in the U.S. It is unclear what factors may
be correlated with these differences in diffusion rates.
2. Background
2.1 Psychotropic Drug Selection
What causes mental health providers to select one treatment option over another? Greater
effectiveness from one product over others in the therapeutic class, the minimization of side
effects and toxicity, marketing and other information, and lower costs of treatment are all
reasons commonly cited in the literature on treatment selection for medical disorders
(Berndt, Bui et al. 1995; Ellison, Cockburn et al. 1997; Berndt, Cockburn et al. 1998;
Berndt, Bhattacharjya et al. 2002; Chintagunta, Jiang et al. 2008). Patient requests and
characteristics, provider characteristics and familiarity with certain products can also play an
important role ((Weiss, Charney et al. 1990; Peay and Peay 1994; Crystal 1995; Hellerstein
1998; Stern and Trajtenberg 1998); also see (Hemminki 1975; Christensen 1981; Bradley
1991) for literature reviews). Another source of variation is the relative contribution of the
new product to the existing treatment class; new “breakthrough” drugs that are substantial
improvements on existing technologies may enter the market more strongly than “me-too”
or imitator products.
2.2 The Influence of Managed Care
It is likely that the insurance setting under which individual physicians practice may play an
important role in explaining variations in prescribing. The strong proliferation of
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pharmaceutical insurance either as a covered benefit in health insurance plans, or as a
separate policy, as is the case with Medicare Part D prescription drug plans, has reduced the
price sensitivity of consumers receiving prescription drugs (Leibowitz, Manning et al. 1985;
Phelps 1997). The managed care era has ushered in a more generous pharmacy benefit for
enrollees, but with it, a greater degree of restrictions on choices of treatment through
formulary design, especially among expensive new products. These changes have likely led
to very real changes in the selection of treatments for many disorders and thus changes in
the diffusion patterns of new technologies. For example, Mas and Seinfeld found a negative
association between HMO penetration and the adoption of 13 different hospital-based
technologies (Mas and Seinfeld 2008).
While the tools of managed care may be declining in the private sector (Swartz 1999), they
are still widely used in Medicaid programs. As of June 2008, more than 70% of Medicaid
enrollees nationwide were in a health plan defined as managed care by the Centers for
Medicare and Medicaid Services (CMS) and the percent of enrollees involved in managed
care plans has continued to increase ((Centers for Medicare and Medicaid Services (CMS)
2009).
As the tools of managed care increasingly penetrate behavioral health insurance, the
diffusion of new psychotropic products into existing treatment options is likely to be
strongly affected. The direction of this effect is ambiguous due to the complexity and
differing incentives inherent in these tools. Managed care plans vary considerably from
strictly capitated models with clear incentives for cost reduction, to more loosely managed
models, such as primary care case management. Mental health carve-outs have been shown
to affect the patterns of care received, shifting care from more costly inpatient care to less
expensive outpatient substitutes (Grazier 1999; Huskamp 1999).
It is not clear what impact, if any, managed care has on the use of newer drug products.
Weiner and colleagues (1991) found no difference between managed care physicians and
their fee-for-service counterparts in terms of the use of new drugs. Domino and Salkever
(2003), however, found that managed care providers in a Medicaid program were more
likely to use the new class of antidepressants, SSRIs, over their colleagues in a gate-keeper
FFS model. Managed care enrollees were also found to be much less likely to receive a
pharmaceutical treatment, indicating an overall negative association between managed care
and newer antidepressant products. Berndt, Frank, and McGuire (1997) found that PPOs and
mental health carve-outs have lower spending on SSRIs as a percentage of all antidepressant
spending over fee-for-service indemnity plans.
Behavioral Health Carve-outs—One type of managed behavioral health care is a mental
health/substance abuse carve-out, found both in the public and private sectors. Insurers
taking a carve-out approach contract all mental health and frequently substance abuse
services to a secondary insurer, which arranges a provider network to provide care. Nineteen
states had waivers for mental health and/or substance abuse carve-outs in their Medicaid
programs by 1998. The carve-out approach is also common among private insurers, with
72% of individuals with health insurance enrolled in specialty behavioral health insurance
plans (U.S. Department of Health and Human Services 1999).
Mental health carve-outs have been shown to have strong effects on the patterns of care
received, shifting care from more costly inpatient care to less expensive outpatient
substitutes (Grazier and Eselius 1999). In most cases prescription drugs are not included in
carve-out arrangements and are covered instead under the primary (general) insurance policy
(Huskamp 2003). New psychotropic medications may be adopted much more readily under
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carve-out arrangements, as providers shift patients onto pharmaceutical care for which the
carve-out vendor is not at risk (Frank, Conti et al. 2005).
The extent to which individuals are shifted onto medications may vary by disease. Ling,
Berndt and Frank (2008) hypothesized that the shift towards pharmaceutical care will be
larger for antidepressant medications than for antipsychotic medications, because of the
improved side effect profile of newer antidepressants has increased the feasibility of use in
general medication settings. They examined the effect of carve-outs on both the total
number of antidepressant and antipsychotic prescriptions and on the shares of particular
classes of these medications and found that carve-outs are associated with more
antidepressant, but fewer antipsychotic prescriptions. They also found lower shares of older
tricyclic antidepressants and greater shares of SSRIs. No significant differences in the shares
of SGAs were found. Busch and colleagues also did not observe differences in the rate of
medication use among persons with schizophrenia after a Medicaid carve-out in one state
(Busch, Frank et al. 2004).
In summary, it is likely that penetration of managed care plans is one of the major influences
on drug diffusion, through increased use of formularies and increased access to outpatient
services, but the direction of the effect is not obvious and may differ across types of
managed care and across drug classes.
3. Conceptual model
The epidemic model is often used to motivate diffusion processes (Stoneman 2002) and
leads to an S-shape. In this model, the world of potential adopters of a durable good or
technology is partitioned into two sets of individuals (or firms), based on whether or not
they have adopted the technology. In the initial period, the set of users is non-zero to avoid a
trivial time path of diffusion. In subsequent time periods, non-users infect or contact users at
a certain rate, generally specified as a linear function of the percent of the total potential
adopters who have already adopted. This contact promotes the conversion of non-users to
users with some fixed probability.
Formally, the standard epidemic model has a population of N potential adopters of a good,
of which M(t) are adopters at any time t (notation follows (Stoneman 2002). The rate at
which non-users contact users is proportional to the current rate of use, specified as ;
the probability that this contact leads to conversion is specified as γ. Therefore, the rate at
which the user population increases over time is
(1)
where ϕ=δγ.
Several extensions to this model lead to ambiguities in the diffusion path. First, users may
also convert to non-users. This can be specified as the infection of users by non-users in the
population and can be modeled as a function of the proportion non-users. This can be
labeled as reverse contagion, information sharing, product failure, or fads that vary
according to a critical mass of users or non-users. For simplicity, I specify that some
fraction, α, of users convert back to non-users by ceasing to purchase the good in a
subsequent period. Therefore, the change in the level of use over time is
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If α >ϕ, then the diffusion rate is negative; α <ϕ leads to an ambiguous result.
Second, under the classic model, if the entry of a competing product leads both users and
non-users of the earlier entrant to convert to the use of the new product, the first and second
derivatives of the diffusion curve similarly become ambiguous. The basic epidemic model
can easily be transformed to allow for the use (or non-use) of two products, assuming
exclusivity in use, according to
(3)
Further, suppose that users of product 1 can switch to product 2 according to
(4)
leaving the total change in users of product 1 as
(5)
The sign of this expression is ambiguous without further information on the relative rate of
adoption and conversion between the two products. Since variation in these rates varies
among products and markets, more complex empirical diffusion models should allow for
increasing as well as decreasing rates of diffusion, and probably both over different stages in
the product lifecycle.
These models lead not only to an ambiguous first derivative, but to ambiguous higher order
derivatives as well. Similar extensions can lead to similar results from other theoretical
models often used to motivate diffusion. Models of Bayesian updating (Phelps 2000), for
example, may also explain changes in use, both positive and negative, as individuals'
posterior beliefs change as they gain information from experience or other users or non-
users.
Finally, it is worth noting that the classical diffusion model considers primarily durable
goods or goods which require a substantial commitment to use such that users do not switch
easily among competing goods. For non-durable goods, such as pharmaceuticals or apples,
the cumulative proportion of individuals or firms who have ever used a product is less
important than the current proportion of potential users purchasing a good. This means that
empirical work will generally focus on estimating a time-varying market share, which is
even less likely to resemble an S-shape.
The monotonically increasing S-shaped curve, then, becomes an empirical question, one that
should be determined by, not required of, empirical evidence. In practice, diffusion curves
may be seen theoretically to take on many shapes (Hahn, Park et al. 1994; Andersen 1999;
Comin, Hobijn et al. 2006; Comin, Hobijn et al. 2008), which means that empirical models
such as the logistic may not provide the flexibility needed to model the diffusion of many
products or technologies.
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The data used for these analyses are the total prescriptions paid by fee-for-service Medicaid
programs in 49 states and the District of Columbia from 1991 – 20051. 1991 is the earliest
year of this data available and data were not used after 2005 because the introduction of
Medicare Part D has substantially affected the level and possibly mix of psychotropic
medication paid for by the Medicaid program. The Medicaid drug utilization data are
reported quarterly and are available from the Center for Medicare and Medicaid Services
(CMS) as the Medicaid Drug Utilization Files. They contain no personal identifiers or
individual characteristics.
4.2 Measures of Drug Use
Prescription lengths vary across individuals and dosage varies across medications, so all
medications used were converted into the World Health Organization's Defined Daily Dose
units (World Health Organization Collaborating Center for Drug Statistics Methodology
2006). DDD units express drug use in standard person-day doses; recommended dosing of
some drug products changed over time and levels contemporaneous to each year are used2.
Thus 10 DDD units indicate the amount of medication that would be prescribed on average
to one person for 10 days or to 10 people for one day. I convert all medication usage into
DDD units and then aggregate into the relevant classes at the state-quarter level. The
dependent variables for each medication class (SSRIs, SNRIs, and SGAs) were expressed as
the percentage of the total DDDs in each quarter for each class of medications
(antidepressants and antipsychotics). Several brand name drugs in these classes lost patent
protecting during the study period (e.g., Prozac the first SSRI, lost protection in 2001); both
generic and brand name drug doses are included in the DDD market share. Observations
with reported shares of 0 or 100% were set to missing as visual inspection confirmed that
these were substantial departures from adjacent observations within states. Robustness
analyses using share of prescriptions were conducted and results are similar to those
reported here.
4.3 Managed Care measures
I examine the association between managed care and psychotropic medication diffusion
using three different measures of managed care. Managed care rates for all three variables
are derived from CMS reports (Centers for Medicare and Medicaid Services (CMS) 2009).
The first definition includes only capitated managed care plans, such as HMOs. It is
expected that more heavily managed plans have greater control over prescribing practices of
providers through tighter formulary design or contractual arrangements with medical
professionals as is the case with staff-model HMOs. The second definition of managed care
is a broader definition, which includes both capitated models as well as more loosely
managed models such as PPOs and primary care case management or gatekeeper models.
While capitated models are a subset of all managed models, the degree to which individuals
may be in both plans cannot be determined in these data, therefore I do not examine non-
capitated managed care models separately. These models are hypothesized to have a lower
1Arizona is the only state that is entirely exempted from the Federal Medicaid program, thus its drug utilization data is not captured.
For simplicity, the 49 states and the District of Columbia are subsequently referred to as “states.” Drug utilization information is not
available for Medicaid enrollees in capitated managed care programs which are at risk for medication expenses, since these claims are
generally paid directly by the capitated health plan, rather than by the Medicaid program.
2Three psychotropic drug products experienced changes in DDDs during our study period: the DDD for two SSRIs, sertraline and
fluvoxamine, changed from 75 MG/day to 50MG/day in 1996 and in 1991, the DDD for risperidone changed from 6MG/day to 5MG/
day). I am grateful to the staff at WHO Collaborating Centre for Drug Statistics Methodology for providing historic data on drug
dosing.
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average level of influence on drug diffusion, given the weaker incentives to manage all
health care costs.
The third definition examines the use of behavioral health carve-outs and is expressed as a
binary variable, indicating whether the state used a carve-out for at least some of its
Medicaid population during the year. The carve-out indicator was derived from annual
Medicaid managed care reports (Centers for Medicare and Medicaid Services (CMS) 2009)
for 1995-2005. Earlier years were taken from Ling, Berndt, and Frank (Ling, Berndt et al.
2008). It is unclear what effect the use of behavioral health carve-outs has on psychotropic
diffusion. States with carve-outs may put greater emphasis on controlling behavioral health
care costs, in which case the diffusion of newer drug products may be more restrictive.
These states, however, may also seek to better manage adverse selection from having health
plans compete to avoid costlier mental health treatment users (Frank, Huskamp et al. 1996)
and therefore may be more concerned with quality of care and access to evidence-based
practices.
The interpretation of the managed care effects vary according to the measure used. The data
cover all prescription medications purchased via fee-for-service in state Medicaid programs
and do not include those medications covered in capitated contracts. Therefore, the effects of
capitated managed care are on fee-for-service medication use and are assumed to indicate
spillover effects, which have been observed in other settings (Baker 1997; Baker 1999;
Domino and Salkever 2003). The broader measure of managed care includes capitated as
well as primary care case management programs, which are largely fee-for-service, and thus
these effects are assumed to be a mix of spillover and direct effects. Mental health carve-
outs are generally not risk-bearing arrangements (Frank, Huskamp et al. 1996) and even if
capitated, do not tend to cover prescription medications. These effects are therefore assumed
to be direct in the sense that prescriptions written by carve-out providers are likely to be
filled in the fee-for-service setting.
4.4 Other explanatory variables
A variety of state characteristics are used as explanatory variables to control for time variant
factors that may be correlated with both the diffusion of psychotropic medication and with
managed care status. These annual measures and their sources are: the state median income,
the percent of the state population with income less than 100% and 200% of the federal
poverty level, the state population (U.S. Census), the state unemployement rate (Bureau of
Labor Statistics), the total state government expenditures, total state Medicaid expenditures
as percent of total general fund expenditures during the state fiscal year (the National
Association of State Budget Offices), and the Federal matching percentage (CMS),
expressing the percentage of total Medicaid expenditures paid for by the Federal
government each year. Expenditure variables are expressed in 2005 dollars and were
deflated by the GDP index. The percent of Medicaid enrollees classified as children or
elderly and the number of physicians in each state were originally considered as explanatory
variables, but contributed little explanatory power and substantially restricted the sample
due to missing observations for some states and years. State-fixed effects are included to
control for remaining state differences that are constant over time.
Absent from these models is the inclusion of other factors that may affect drug diffusion,
such as physician detailing by drug company representatives or other forms of advertising,
either in technical journals or direct to consumers. There are several reasons for this.
Nationwide information sources such as advertising, FDA updates, or scientific publications
will not promote state-level differences, and are thus factored into the overall time trends.
Advertising efforts, especially detailing, that are likely to vary across states may be
correlated with managed care. Drug detailing efforts, for example, may be lower in areas
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with greater managed care since drug decisions are likely to be more tightly controlled by
formulary design, over which individual physicians have little control. In addition, physician
time for drug detailing visits may be more constrained in managed care settings. Finally,
local direct-to-consumer advertising efforts for antidepressants have been shown to be a
small fraction of national advertising campaigns for prescription medications (Meyerhoefer
and Zuvekas 2008), and therefore will likely not contribute much to the state-level
differences explored here. In addition, some states had changes in prescribing authority
given to nurse practitioners during the study period; these effects may again be part of the
managed care effect. Therefore, I do not separately control for levels of marketing efforts or
changes in prescribing authority, although I certainly acknowledge the important effect on
drug diffusion these efforts have (Berndt, Bhattacharjya et al. 2002; Kravitz, Epstein et al.
2005).
4.5 Model Specification
Dependent variables reflecting the proportion of the FFS Medicaid market accounted for by
new psychotropic technologies are analyzed with fourth-order polynomial regression models
with state fixed effects. This modeling approach does not impose an S-shape as do standard
logistic models and has marginal effects that are easier to interpret (Domino 2009). I pool
data across states and use state fixed-effects models to examine diffusion models on
quarterly data, with managed care penetration over time as the key explanatory variable.
Managed care penetration is interacted with the fourth order time polynomial to determine
how managed care has affected not only the level of use, but the path of diffusion. The final
model specification is:
Where t indexes quarters from 1991-2005, MC is specified as one of the three managed care
definitions described above, Z are other time-varying state characteristics, μ are state fixed
effects, and ε are independently distributed disturbances. Robust standard errors are
reported.
The decision to use a 4th order polynomial instead of other higher or lower terms is
somewhat arbitrary. I ran a Wald test on the significance of the 4th order terms in all models
and rejected the null that these terms are jointly zero in seven out of nine models. In 5th
order models, I also rejected the null hypothesis that the 5th order terms were jointly zero in
all nine models. The improvement in the mean square prediction error, one measure of the
loss function, between the 4th and 5th order models was small (4.0E-04 to 2.0E-06,
representing between a 0.6% and 11.1% improvement) as was the improvement from the 3rd
to 4th order models (1.0E-07 to 3.9E-04 or 0.06% to 10.4%). However, plots of diffusion
curves from 5th order models showed considerably greater out-of-range predictions (e.g., at
time=1, the SSRI shares ranged from 0.02 to 0.59. Predictions from the 4th order capitated
model ranged from 0.22 to 0.52 whereas predictions from the 5th ordered capitated model
ranged from 0.25 to 0.86). Only results from the slightly more parsimonious 4th order model
are reported.
There is the potential for the endogeneity of managed care with the diffusion variables
measured here. That is, managed care firms may strategically enter markets according to
levels of health care use and competition (Baker 1997; Ellis and Gurol 2002). Using the
same data, Ling, Berndt and Frank examined the endogeneity of mental health carve-outs
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with the number of psychotropic prescriptions and did not find strong evidence of
endogeneity (Ling, Berndt et al. 2008). In this manuscript, our dependent variables focus on
the composition rather than the size of the psychotropic drug markets and therefore the
exogeneity of managed care may be a reasonable assumption.
5. Results
The rates of drug adoption showed significant variation across states and time periods (Table
1). The mean SSRI use was 23% of all antidepressants in 1991, four years after their
introduction, ranging across states from almost none to 71%. The SSRI use rate in 2005 was
74%, ranging from 64% to 82%. SNRIs had a much lower level of use; in 1995 just under
3% of all DDD units were for this class of antidepressants, growing to 9% by 2005. Atypical
antipsychotics demonstrated an even more remarkable diffusion rate, comprising only 4% of
daily dose antipsychotic units in 1991, but reaching 92% by 2005. Managed care rates also
varied considerably across states and over time. In 1991, states only had an average of 2.9%
of Medicaid enrollees in capitated plans and only 2% of states (that is, one state) had mental
health carve-outs. By 1995, 11% of enrollees were in capitated plans, 29% of enrollees were
in any type of managed care plan, and 14% of states had carve-outs. A decade later, in 2005,
30% of Medicaid enrollees were in capitated plans, 64% were in any type of managed care
program, and 33% of states had carve-outs.
Results from the polynomial models show that capitated managed care was consistently
associated with a large increase in the share of new psychotropic medications in the initial
time period, controlling for time trends (Table 2); this effect was not significant for SSRIs.
The uninteracted managed care variable indicates that a ten percentage point increase in the
use of capitated managed care is associated with between a 2.7 (SNRIs) and 10.1 (SGAs)
percentage point increase in the use of these newer classes of psychotropic medications in
the initial period.
Figure 1 plots the predicted diffusion path for these three classes during the study period at
five different levels of capitated managed care3. Early in the diffusion process, states with
greater use of capitated payments in their Medicaid programs had higher levels of new
psychotropic medication use in contrast to states with no capitation, indicating a strong
spillover effect in innovation from these programs. By the mid 1990s, the levels of use
across states converged and have stayed fairly similar. In exploratory analyses to further
investigate this finding, I ran models on drug-specific shares for three of the atypical
products, separately by time periods prior to 2000 and those from 2000-2005 (results
available by request). The Wald test on the capitated managed care terms was significant in
models prior to 2000, but not after this time period, consistent with the finding that capitated
managed care was associated with more rapid diffusion early in the study period.
Including non-capitated models in the definition of managed care lowers the association
between managed care and drug diffusion. This broader uninteracted managed care term was
significant only in SGA model. The managed-care – time interactions were largely
individually insignificant, although the Wald test of joint significance is significant at the
0.05 level for both the SSRI and SGA models. The predicted diffusion curve for SGAs at
varying levels of managed care (Figure 2) again confirms a path largely independent of this
broader measure of managed care involvement (as well as a fairly sigmoidal shape).
3It should be noted that only 2 states had 100% capitated Medicaid programs at any point, although 4 states had capitation rates of
95% or greater. Figure 1c demonstrates the downside of the 4th order polynomial model: overfitting of the model resulted in too large
an estimated spread in the initial time periods.
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The use of behavioral health carve-outs was associated with much smaller increases in the
level of newer psychotropic medication use and the uninteracted carve-out term was only
significant in the SGA model (Table 2 & Figure 3). Although I reject the hypothesis that the
diffusion paths are the same between carve-out and non-carve-out states, the magnitude of
the difference in diffusion paths is small. SGAs are seen to have an initially higher level of
use in carve-out states, followed by a substantial decline in use, until the diffusion paths
converge in 1997.
4. Discussion
I found evidence of differences in diffusion paths of newer psychotropic medications using
three different definitions of managed care used by state Medicaid programs. In particular,
capitated managed care programs strongly increased the initial rate of diffusion of all three
medication classes examined here and changed the shape of the diffusion curve.
These results may indicate that the spread of capitated managed care plans in state Medicaid
programs may have been partially responsible for the strong early launches of newer classes
of psychotropic medications, especially SSRIs and SGAs. While much remains to be learned
about the diffusion of medical technologies, the greater level of initial use likely serves as a
catalyst for further diffusion as prescribers learn about new medications from their patients
and their colleagues (Coscelli and Shum 2004; Domino, Frank et al. 2009) and develop
norms for further use (Frank and Zeckhauser 2007).
These results expand on the Ling, Berndt, and Frank (Ling, Berndt et al. 2008) findings in
several ways. First, I examine three different types of managed care programs. Second, if I
remove the managed care-time interactions and many of the state covariates from our SSRI
and SGA carve-out models, I replicate their results. However, these interactions point to
significant differences in the time path of diffusion, not just the level of use. In particular, I
find that carve-outs have statistically significant different diffusion paths (Table 2) with
slightly lower initial levels of use of SSRIs and greater initial shares of SGAs. Figure 3
makes it clear that the rate of use of these newer classes of psychotropic medications are not
unambiguously higher (or lower) throughout the study period.
A number of limitations should be noted. The aggregate data used here do not allow for
examination of subpopulations which may be more likely to have demonstrable effects of
managed care on drug diffusion. The DDD conversion assumes a constant dosing level,
which may not reflect the actual patient doses. Off-label uses of psychotropic medications,
particularly present in psychotropic medications (Radley, Finkelstein et al. 2006; Domino
and Swartz 2008), may be more likely to be curtailed under managed care, but cannot be
examined with these data since accompanying diagnostic information is not available.
Aggregate level data also do not allow for models of diffusion at the extensive versus
intensive margins. That is, I cannot tell whether the diffusion curves modeled here are
motivated by increases in the number of users, or increases in the dosing or compliance rate
for existing users. Other authors have found that increases in medication use translated to a
greater treated population (Berndt, Bhattacharjya et al. 2002; Frank and Glied 2006).
Domino and Swartz (2008) found that the diffusion of atypical antipsychotics was
accomplished not through greater compliance or dosing, but because of substantial growth in
the number of off-label users and antipsychotic users with newer on-label conditions. In
addition, I cannot determine the level of polypharmacy, nor whether increases in the rate of
polypharmacy have contributed to changes in the diffusion path. Factors such as drug
characteristics, marketing effects, FDA updates, scientific publications, and other sources of
information, as well as individual and physician characteristics may also have important
effects but because of their association with managed care are not the focus of this paper.
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Finally, I also cannot place a value on greater diffusion since our data do not contain
information on clinical outcomes nor on the prevalence of disease by state. Skinner and
Staiger (2009), for example, found a large association between the diffusion of innovations
in heart attack treatments and productivity outcomes and patient survival.
Given the recent controversy over whether SNRIs and SGAs really have delivered on early
promises of cost-effectiveness and the greater incentives to manage health care expenditures
in capitated health insurance plans (Barrett, Byford et al. 2005; Rosenheck, Leslie et al.
2006), it is somewhat surprising that the greater use of these plans are seen to be associated
with greater use of these costlier medication classes. The fact that the rates of use quickly
converged to that of non-managed plans may indicate the greater efficiency with which
capitated plans affect change by providers, with a substantial showing in the early years of
these medications and a stronger cooling off period as more information was available on
these newer psychotropic agents.
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Reviewer Appendix: Models on other antidepressants and antipsychotics
Table 3
Coefficients (robust standard errors) from 4th order
polynomial fixed effect regression models of diffusion of
older antidepressant and antipsychotic medication












































































































Figure 4. The Predicted Retraction Path of Older Psychotropic by Level of Capitated Managed
Care Enrollment in State
Figure 4a: Non-SSRI or SNRI Antidepressants
Figure 4b: First generation antipsychotics
References
Andersen B. The Hunt for S-shaped Growth Paths in Technological Innovation: a Patent Study.
Journal of Evolutionary Economics. 1999; 9:487–526.
Baker LC. The Effect of HMOs on Fee-for-Service Health Care Expenditures: Evidence from
Medicare. Journal of Health Economics. 1997; 16(4):453–481. [PubMed: 10169101]
Domino Page 12













Baker LC. Association of Managed Care Market Share and Health Expenditures for Fee-for-Service
Medicare Patients. JAMA. 1999; 281(5):432–437. [PubMed: 9952203]
Barrett B, Byford S, et al. Evidence of cost-effective treatments for depression:a systematic review.
Journal of Affective Disorders. 2005; 84(1):1–13. [PubMed: 15620380]
Berndt ER, Bhattacharjya A, et al. An Analysis of the Diffusion of New Antidepressants: Variety,
Quality, and Marketing Efforts. The Journal of Mental Health Policy and Economics. 2002; 5:3–19.
[PubMed: 12529566]
Berndt ER, Bui L, et al. Information, Marketing and Pricing in the U.S. Anti-Ulcer Drug Market.
American Economic Review. 1995; 85(2):100–105. [PubMed: 10160519]
Berndt, ER.; Cockburn, IM., et al. Is Price Inflation Different for the Elderly? An Empirical Analysis
of Perscription Drugs. In: Garber, A., editor. Frontiers in Health Policy Research. Vol. 1.
Cambridge, Massachusets: MIT Press; 1998. p. 33-75.
Berndt ER, Frank G Richard, et al. Alternative Insurance Arrangements and the Treatment of
Depression: What are the Facts? American Journal of Managed Care. 1997; 3(2):135–143.
[PubMed: 10169245]
Bradley CP. Decision Making and Prescribing Patterns- a Literature Review. Family Practice- an
International Journal. 1991; 8(3):276–287.
Busch AB, Frank RG, et al. The Effect of a Managed Behavioral Health Carve-out on Quality of Care
for Medicaid Patients Diagnosed as Having Schizophrenia. Archives of General Psychiatry. 2004;
61:442–448. [PubMed: 15123488]
Centers for Medicare and Medicaid Services (CMS). Medicaid Managed Care Enrollent Reports,
various years. 2009. Retrieved October 28, 2009, from
http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/04_MdManCrEnrllRep.asp
Chintagunta, P.; Jiang, R., et al. NBER Working Paper Series. Cambridge, MA: NBER; 2008.
Information, Learning, and Drug Diffusion: The Case of Cox-2 Inhibitors.
Christensen DB, B Patricia J. Drug Prescribing: Patterns, Problems, and Proposals. Social Science and
Medicine. 1981; 15A:343–355.
Comin, D.; Hobijn, B., et al. NBER Working Paper Series. Cambridge, MA: 2006. Five Facts You
Need to Know about Technology Diffusion.
Comin D, Hobijn B, et al. A new approach to measuring technology with an application to the shape of
the diffusion curves. Journal of Technology Transfer. 2008; 33(2):187–207.
Coscelli A, Shum M. An empirical model of learning and patient spillovers in new drug entry. Journal
of Econometrics. 2004; 122(2):213–246.
Crystal S, Sambamoorthi U, Merzel C. The Diffusion of Innovation in AIDS Treatment--Zidovudine
Use in Two New Jersey Cohorts. Health Services Research. 1995; 30(4):593–614. [PubMed:
7591783]
Domino, ME. A Flexible Functional Form for Diffusion Research. Chapel Hill, NC: UNC; 2009.
Domino, ME.; Frank, RG., et al. The Diffusion of Antipsychotic Medications: Does the Close-
Knittedness of Provider Networks Matter?. Chapel Hill, NC: UNC; 2009.
Domino ME, Salkever DS. Price Elasticity and Pharmaceutical Selection: the Influence of Managed
Care. Health Economics. 2003; 12(7):565–586. [PubMed: 12825209]
Domino ME, Swartz MS. Who are the New Users of Antipsychotic Medications? Psychiatric Services.
2008; 59(5):507–514. [PubMed: 18451006]
Drake R, Skinner J, et al. What Explains the Diffusion of Treatments for Mental Illness? American
Journal of Psychiatry. 2008; 165(11):1385–1392. [PubMed: 18981070]
Ellis RP, Gurol I. Health Plan Entry and Exit in the Medicare Managed Care Market. 2002
Ellison SF, Cockburn I, et al. Characteristics of demand for pharmaceutical products: an examination
of four cephalosporins. RAND Journal of Economics. 1997; 28(3):426–446. [PubMed: 11794359]
Frank RG, Conti RM, et al. Mental Health Policy and Psychotropic Drugs. The Milbank Quarterly.
2005; 83(2):271–98. [PubMed: 15960772]
Frank, RG.; Glied, SA. Better But Not Well: Mental Health Policy in the United States since 1950.
Baltimore, MD: The Johns Hopkins University Press; 2006.
Domino Page 13













Frank RG, Huskamp HA, et al. Some economics of mental health carve-outs. Archives of General
Psychiatry. 1996; 53(10):933–937. [PubMed: 8857870]
Frank RG, Zeckhauser RJ. Custom-made versus ready-to-wear treatments: Behavioral propensities in
physicians' choices. Journal of Health Economics. 2007; 26:1101–1127. [PubMed: 18031852]
Goldman D, Smith JP. Socioeconomic Differences in the Adoption of New Medical Technologies.
American Economic Review. 2005; 95(2):234–237.
Grazier K, Eselius LL, Hu TW, Shore KK, G'Sell WA. Effects of a Mental Health Carve-out on Use,
Costs and Payers; a Four-year Study. Journal of Behavioral Health Services and Research. 1999;
26(4):381–389. [PubMed: 10565099]
Grazier KL, Eselius LL. Mental Health Carve-Outs: Effects and Implications. Medical Care Research
and Review. 1999; 56(Supplement 2):37–59. [PubMed: 10327823]
Griliches Z. Hybrid Corn: an Exploration in the Economics of Technological Change. Econometrica.
1957; 25(4):501–522.
Hahn M, Park S, et al. Analysis of New Product Diffusion Using a Four-Segment Trial Repeat Model.
Marketing Science. 1994; 13(3):224–247.
Hellerstein JK. The importance of the physician in the generic versus trade-name prescription decision.
RAND Journal of Economics. 1998; 29(1):108–136. [PubMed: 10182437]
Hemminki E. Review of Literature on the Factors Affecting Drug Prescribing. Social Science and
Medicine. 1975; 9:111–115.
Huskamp HA. Episodes of Mental Health and Substance Abuse Treatment Under a Managed
Behavioral Health Care Carve-out. Inquiry. 1999; 36:147–161. [PubMed: 10459370]
Huskamp HA. Managing Psychotropic Drug Costs: Will Formularies Work? Health Affairs. 2003;
22(5):84–96. [PubMed: 14515884]
Kessler R, Merikangas K, et al. Prevalence, comorbidity, and service utilization for mood disorders in
the United States at the beginning of the twenty-first century. Annual Review of Clinical
Psychology. 2007; 3:137–58.
Kravitz RL, Epstein RM, et al. Influence of Patients' Requests for Direct-to-Consumer Advertised
Antidepressants: A Randomized Controlled Trial. JAMA. 2005; 293(16):1995–2002. [PubMed:
15855433]
Leibowitz, A.; Manning, WG., et al. A RAND Note N-2278-HHS. 1985. The Demand for Prescription
Drugs as a Function of Cost-Sharing.
Ling DC, Berndt ER, et al. Economic Incentives and Contracts: The Use of Psychotropic Medications.
Contemporary Economic Policy. 2008; 26(1):49–72.
Mark TL, Levit KR, et al. Mental Health Treatment Expenditure Trends, 1986–2003. Psychiatric
Services. 2007; 58(8):1041–1048. [PubMed: 17664514]
Mas N, Seinfeld J. Is Managed Care Restraining the Adoption of Technology by Hospitals? Journal of
Health Economics. 2008; 27:1026–1045. [PubMed: 18417230]
Meyerhoefer CD, Zuvekas SH. The Shape of Demand: What Does It Tell Us about Direct-to-
Consumer Marketing of Antidepressants? The BE Journal of Economic Analysis & Policy. 2008;
8(2):1–32.
Peay MY, Peay ER. Innovation in High Risk Drug Therapy. Social Science and Medicine. 1994;
39(1):39–52. [PubMed: 8066486]
Phelps, CE. Health Economics. Reading, Massachusetts: Addison-Wesley; 1997.
Phelps, CE. Information Diffusion and Best Practice Adoption. In: Culyer, AJ.; Newhouse, JP.,
editors. Handbook of Health Economics. Vol. 1A. Amsterdam: Elsevier; 2000. p. 223-264.
Radley DC, Finkelstein SN, et al. Off-label Prescribing Among Office-based Physicians. Archives of
Internal Medicine. 2006; 166(9):1021–1026. [PubMed: 16682577]
Rosenheck RA, Leslie DL, et al. Cost-effectiveness of second-generation antipsychotics and
perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of
Psychiatry. 2006; 163(12):2080–2089. [PubMed: 17151158]
Skinner, J.; Staiger, D. NBER Working Paper Series. Cambridge: NBER; 2009. Technology Diffusion
and Productivity Growth in Health Care.
Domino Page 14













Skinner, JS.; Staiger, D. Technology Adoption from Hybrid Corn to Beta Blockers. In: Berndt, ER.;
Hulten, CR., editors. Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches.
Chicago: University of Chicago Press; 2007.
Soni, A. The Top Five Therapeutic Classes of Outpatient Prescription Drugs Ranked by Total Expense
for Adults Age 18 and Older in the U.S. Civilian Noninstitutionalized Population, 2006. Statistical
Brief #232. January. 2009 Retrieved July 20, 2009, from
http://www.meps.ahrq.gov/mepsweb/data_files/publications/st232/stat232.pdf
Stern S, Trajtenberg M. Empirical Implications of Physician Authority in Pharmaceutical
Decisionmaking. draft. 1998
Stoneman, P. The Economics of Technological Diffusion. Oxford: Blackwell Publishers; 2002.
Swartz K. The Death of Managed Care as We Know It. Journal of Health Politics, Policy and Law.
1999; 24(5):1201–1205.
U.S. Department of Health and Human Services. Mental Health: A Report of the Surgeon General.
Rockville, Maryland: U.S. Department of Health and Human Services, Substance Abuse and
Mental Health Services Administration, Center for Mental Health Services, National Institutes of
Health, National Institute of Mental Health; 1999.
Weiner JP, Lyles A, et al. Impact of Managed Care on Prescription Drug Use. Health Affairs. Spring;
1991 :140–154. [PubMed: 2045046]
Weiss R, Charney E, et al. Changing Patient Managment: What Influences the Practicing Pediatrician?
Pediatrics. 1990; 85(5):791–795. [PubMed: 2330241]
Wells KB. Caring for Depression in America: Lessons Learned from Early Findings of the Medical
Outcomes Study. Psychiatric Medicine. 1991; 9(4):503–519. [PubMed: 1749834]
World Health Organization Collaborating Center for Drug Statistics Methodology. The ATC/DDD
System. 2006. Retrieved September 15, 2006, from http://www.whocc.no/atcddd/
Domino Page 15













Figure 1. The Predicted Diffusion Path of New Psychotropic by Level of Capitated Managed
Care Enrollment in State
Figure 1a: SSRI diffusion
Figure 1b: SNRI Diffusion
Figure 1c: SGA Diffusion
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Figure 2. The Predicted Diffusion Path of Second Generation antipsychotics by enrollment in
any type of Managed Care
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Figure 3. The Predicted Diffusion Path of New Psychotropic Medications by Carve-out status
Figure 3a: SSRI diffusion
Figure 3b: SNRI Diffusion
Figure 3c: SGA Diffusion
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